Skip to main content

Table 1 Clinical course for Patients 1, 2, and 3 with MPS IVA

From: Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study

 

Patient 1

Patient 2

Patient 3

Current age

17 years, 8 months

13 years, 1 month

6 years, 2 months

Type of genetic analysis

Whole-exome sequencing

Whole-exome sequencing

Targeted GALNS sequencing

Results of GALNS gene analysis

 c. 964G > C, p. A322P (paternally inherited, novel missense, variant of unknown significance)

 c. 611A > G, p. N204S (maternally inherited, novel missense, variant of unknown significance)

Age at onset of symptoms

5 years

5 years

3 years

Age at diagnosis

14 years, 7 months

10 years

3 years, 1 month

Age at initiation of ERT

14 years, 8 months

10 years, 1 month

3 years, 2 months

  1. ERT enzyme replacement therapy, MPS IVA mucopolysaccharidosis type IVA